Precision Oncology Market: Genomics, AI and Targeted Therapies Reshape Personalized Cancer Care

The Precision Oncology Market is undergoing rapid transformation as healthcare systems increasingly move toward molecularly guided diagnosis, personalized treatment, and biomarker-driven cancer care. According to Maximize Market Research, the global Precision Oncology Market was valued at USD 118.8 billion in 2025 and is projected to reach approximately USD 230.04 billion by 2032, expanding at a CAGR of 9.9% during 2026–2032. The rising global cancer burden is a major growth driver, increasing demand for genomic profiling, biomarker testing, next-generation sequencing (NGS), liquid biopsy, targeted therapies, and companion diagnostics. Advances in artificial intelligence, multi-omics, real-world data analytics, and molecular diagnostics are enabling healthcare providers to identify actionable mutations and improve treatment selection. The market also presents significant opportunities through earlier molecular detection, non-invasive liquid biopsy, AI-assisted pathology, and integration of genomic information with clinical records. Pharmaceutical and biotechnology companies are increasingly investing in biomarker-driven drug development and companion diagnostics, creating opportunities for diagnostic providers and technology companies. However, high testing costs, limited reimbursement, complex data management, regulatory requirements, and unequal access to advanced genomic infrastructure remain important barriers.

* Discover Profitable Growth Opportunities: https://www.maximizemarketresearch.com/request-sample/188401/ 

U.S. Market Trends and Investment

The United States remains a major center for precision oncology because of its advanced healthcare infrastructure, strong biotechnology ecosystem, high adoption of genomic testing, and concentration of leading diagnostic and pharmaceutical companies. In 2025, investment increasingly focused on combining genomic data with artificial intelligence and clinical information. Tempus AI announced multi-year strategic collaborations with AstraZeneca and Pathos in April 2025 to develop a multimodal foundation model for oncology, with the agreements including USD 200 million in data licensing and model-development fees. The initiative is designed to use de-identified oncology data to support biomarker discovery, drug-target identification, and therapeutic development. In another important development, Roche received FDA Breakthrough Device Designation in April 2025 for an AI-driven companion diagnostic for non-small cell lung cancer, combining immunohistochemistry with digital pathology. These developments highlight the U.S. shift toward AI-powered diagnostics, multimodal data analysis, and integrated precision-treatment strategies. The FDA's Precision Oncology Program also supports regulatory science intended to accelerate development of better oncology drugs, diagnostics, and biologics.

Largest Market Segments

By product type, the Therapeutics segment dominated the Precision Oncology Market in 2025 and is expected to maintain its leading position throughout the forecast period. Targeted therapies, immunotherapies, and biomarker-driven treatments are supporting the segment, while companion diagnostics increasingly connect molecular testing with targeted drug selection. Continued investment in oncology drug pipelines is expected to reinforce therapeutics demand.

By cancer type, Lung Cancer dominated the market in 2025. Precision oncology has a particularly strong role in lung cancer because molecular testing is routinely used to identify actionable biomarkers, including EGFR, ALK, ROS1, BRAF, KRAS, and MET alterations, which can guide targeted treatment decisions.

Precision Oncology Market Key Players:
North America
Illumina, Inc. – United States
Thermo Fisher Scientific Inc. – United States
Agilent Technologies, Inc. – United States
Foundation Medicine, Inc. – United States
Tempus AI, Inc. – United States
Caris Life Sciences – United States
NeoGenomics Laboratories, Inc. – United States
Exact Sciences Corporation – United States
Guardant Health, Inc. – United States
Natera, Inc. – United States
Myriad Genetics, Inc. – United States
Freenome Holdings, Inc. – United States
Bristol Myers Squibb Company – United States
Pfizer Inc. – United States
Amgen Inc. – United States
Merck & Co., Inc. – United States
Eli Lilly and Company – United States
Gilead Sciences, Inc. – United States
AbbVie Inc. – United States
Johnson & Johnson – United States
Laboratory Corporation of America Holdings (Labcorp) – United States
Flatiron Health, Inc. – United States
PathAI, Inc. – United States
ConcertAI – United States
Quest Diagnostics Incorporated – United States
Charles River Laboratories International, Inc. – United States
IQVIA Holdings Inc. – United States
ICON plc – United States operations

Competitive Analysis

The MMR report identifies Illumina, Thermo Fisher Scientific, Agilent Technologies, Foundation Medicine, and Tempus AI among the leading companies in the Precision Oncology Market. The accessible report does not provide individual 2025 market-share percentages for these companies, so unsupported share figures are excluded.

Illumina strengthened its precision-oncology portfolio in 2025 through regulatory and companion-diagnostic expansion. In May 2025, Japan's Ministry of Health, Labour and Welfare approved TruSight Oncology Comprehensive, a test analyzing DNA and RNA variants across more than 500 genes to identify actionable biomarkers and support targeted therapy selection. In September, Illumina announced partnerships with pharmaceutical companies to develop companion diagnostics for KRAS alterations using its TruSight Oncology platform.

Thermo Fisher Scientific continues to expand oncology-focused NGS and companion-diagnostic capabilities, supporting pharmaceutical companies and clinical laboratories in biomarker identification and precision-treatment development. Its broad molecular-testing ecosystem positions the company to benefit from increasing adoption of comprehensive genomic profiling.

Agilent Technologies remains active in molecular diagnostics and pathology technologies supporting biomarker identification. Its analytical and diagnostic platforms contribute to the broader movement toward increasingly detailed molecular characterization of tumors.

Foundation Medicine significantly advanced its precision-oncology position in 2025. In December, the company announced that it had reached 100 approved and active companion diagnostic indications across the United States and Japan. Its portfolio spans FoundationOne CDx and FoundationOne Liquid CDx, strengthening the connection between genomic profiling and targeted treatment.

Tempus AI is combining genomic, clinical, and AI capabilities to accelerate precision medicine. Its 2025 collaboration with AstraZeneca and Pathos represents a major move toward multimodal oncology foundation models capable of supporting drug discovery, biomarker analysis, and therapeutic development.

Regional Analysis

USA: The United States is a leading precision-oncology market, supported by advanced healthcare infrastructure, genomic-testing adoption, pharmaceutical investment, FDA-supported companion diagnostics, and major companies such as Illumina, Foundation Medicine, Guardant Health, and Tempus.

UK: The UK benefits from expanding genomic medicine programs and a strong life-sciences ecosystem. Companies such as AstraZeneca and Oxford Nanopore Technologies contribute to the development of targeted therapies and genomic technologies.

Germany: Germany's advanced healthcare infrastructure, pharmaceutical industry, cancer-care capabilities, and investment in molecular diagnostics support precision-oncology adoption. Bayer and other established life-sciences companies are active in the broader ecosystem.

France: France benefits from strong pharmaceutical and biotechnology capabilities, growing genomic-medicine adoption, and expanding use of molecular diagnostics in cancer care.

Japan: Japan is strengthening precision oncology through regulatory adoption of advanced genomic testing. Illumina's 2025 approval for TruSight Oncology Comprehensive demonstrates expanding access to comprehensive tumor profiling. Foundation Medicine also reported 43 approved companion-diagnostic indications in Japan by December 2025.

China: China represents an important growth opportunity because of its large cancer burden, expanding healthcare infrastructure, and increasing investment in NGS and biotechnology. MMR identifies BGI Genomics, MGI Tech, Burning Rock Biotech, and other companies as important participants in the regional ecosystem.

MMR identifies North America as the leading regional market, while Asia Pacific offers substantial future growth potential because of its large cancer burden and expanding genomic-medicine capabilities.

Related Reports: 

Global Microbial Products Market https://www.maximizemarketresearch.com/market-report/global-microbial-products-market/54098/ 

Global Recombinant Vector Vaccine Market https://www.maximizemarketresearch.com/market-report/global-recombinant-vector-vaccine-market/84021/ 

Digital PCR (dPCR) and Realtime PCR (qPCR) Market https://www.maximizemarketresearch.com/market-report/global-digital-pcr-dpcr-and-real-time-pcr-qpcr-market/32992/ 

Conclusion

The Precision Oncology Market is moving from a specialized diagnostic approach toward an integrated ecosystem connecting genomics, AI, molecular diagnostics, targeted therapies, and real-world clinical data. In our view, the greatest opportunity lies in making comprehensive genomic testing faster, more affordable, and more clinically actionable. Liquid biopsy, AI-powered pathology, multi-omics, companion diagnostics, and multimodal oncology platforms can expand precision treatment across more cancer types and patient populations. Companies that combine strong clinical evidence with scalable genomic technologies, data analytics, and pharmaceutical partnerships will be best positioned to capture the market's projected expansion to USD 230.04 billion by 2032.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 sales@maximizemarketresearch.com